MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for alleged violations of securities laws, specifically related to false and misleading statements made by the company during the class period from August 7, 2024, to February 24, 2025 [1][2][4] Summary by Sections Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against Maravai LifeSciences Holdings, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - Investors who purchased securities during the specified class period are encouraged to contact the firm before May 5, 2025, to participate in the lawsuit [2] Allegations Against the Company - The complaint alleges that Maravai made false and misleading statements to the market, failed to maintain adequate internal controls over financial reporting, improperly recognized revenue from certain transactions in fiscal 2024, and overstated its goodwill [4] - As a result of these actions, the company's public statements were deemed false and materially misleading throughout the class period, leading to investor damages when the truth was revealed [4]